May 22, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Omeros reports $15.1 million quarterly net loss
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Omeros reported a net loss of $15.1 million, or $0.34 per share, in the first quarter of 2017 compared with a net loss of $20.5 million, or $0.54 per share, in the same quarter last year, according to a company press release.
Total revenues were $12.3 million, which were all related to sales of Omidria (phenylephrine 1% and ketorolac 0.3% injection). In the same quarter of 2016, total revenues were $7.2 million from Omidria sales and $173,000 in grants.
Total costs and expenses for the quarter were $25 million compared with $26.9 million last year.